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There will never be a medical justification for smoking tobacco or using smoke-cured, tobacco products.  
Nevertheless, a recent non-peer-reviewed meta-analysis suggests that smoking may reduce the risk of 
hospitalization with COVID-19 1.  An early study of COVID-19 patients in Wuhan reported a value of 6% for 
the prevalence of smoking in 78 patients 2.  More recent (April, 2020), peer-reviewed studies report that 
Chinese and American patient populations hospitalized for COVID-19 present a prevalence for smoking 
that is markedly lower than (or insignificantly different from) that of the surrounding population 2-4.  A 
non-peer-reviewed paper makes similar claims about French COVID-19 patients 5. In the meta-analysis 
cited above 1, values of smoking prevalence reported for Chinese COVID-19 patients range from 1.4% to 
12.6%, with an overall prevalence of 6.5% in a population of 5960 patients (13 studies).  In contrast, 
smoking prevalence for the Chinese population at large is estimated to be 26.65%.  Thus, Chinese smokers 
appear to be less frequently counted among COVID-19 patients than among the population at large.  
Similar findings are reported for American and French COVID-19 patients.   
Do these data mean that smoking protects smokers from being hospitalized with COVID-19? 
Frankly, it seems unlikely that smoking prevents viral exposure or viral entry into the respiratory system.  
However, it is conceivable that, once the virus enters the airways, a cellular / pharmacological mechanism 
allows nicotine or smoking to reduce the initial probability, or severity, of disease progression. Our 
research group has spent decades conducting research on the molecular actions of nicotine.  It is of course 
possible, and perhaps eventually testable in animal models, that events downstream from interactions 
between nicotine and nicotinic acetylcholine receptors (nAChRs) (including α4β2, α3β4, and/or α7 
nAChRs) exert protection against COVID-19. These mechanisms could include changes in angiotensin 
converting enzyme 2 (ACE2) levels 6,7 and/or suppression of inflammatory pathways 8,9.  Treatment with 
nicotine patches, nicotine gum, or even electronic nicotine delivery systems (ENDSs) could provide 
nicotine without the other harmful effects of smoking. 
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Yet, once COVID-19 patients are admitted to the hospital, any hypothesized protection apparently 
disappears.  There is no evidence that smokers admitted to hospitals present less severe COVID-19 
symptoms than non-smokers.  Two meta-analyses show that smoking either increases, or does not affect, 
the odds ratio for finding smokers in the severely ill COVID-19 population.  In fact, an extensive meta-
analysis of the association between smoking and COVID-19 severity reports an overall two-fold increase 
in the odds ratio for finding smokers among the severe COVID-19 patients, and the increase is significant 
2.   Inclusion in the severe COVID-19 patient group was based on the American Thoracic Society guidelines 
for community-acquired pneumonia 4.  A less extensive meta-analysis reports no significant association 
between active smoking and COVID-19 severity  10.  Thus, smoking “protection”—if it exists--appears to 
apply only to non-hospitalized individuals.  These surprising results call for confirmation and mechanistic 
explanations. 
Other than the cellular / pharmacological “protection” mechanisms briefly described above, one 
can envision at least two straightforward, alternative explanations for the reduced prevalence of smokers 
in the COVID-19 patient population.  The first explanation is systematic bias in identifying smokers in the 
hospital patient population, compared to the general population.  The second is “reverse causation”.  
Hospital admissions staff could systematically underestimate the number of smokers among 
COVID-19 patient because (1) patients fail to inform hospital staff of their smoking history or (2) obtaining 
accurate medical histories under emergency conditions is problematic.  For example, urine testing of 
hospitalized patients in Australia for the nicotine metabolite cotinine revealed that the admissions staff 
under-counted active or previous smokers by 37% because patients failed to accurately inform staff about 
their smoking behavior 11.  Previous studies by survey methodologists show that face-to-face interviews 
can introduce biases in certain types of attitudinal and behavioral questions not present in self-completion 
interviews 12,13.  Subjects in face-to-face interviews may be unwilling to admit socially undesirable behavior 
and attitudes under direct questioning 14.  In contrast to face-to-face interviews, government agencies 
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and academic researchers find no evidence for strong social desirability bias in self-reported surveys of 
smoking behavior 15-17.   Considering the conditions under which COVID-19 patients may be interviewed 
during hospital admission, there are justifiable reasons to suspect the accuracy of smoking histories 
obtained from these interviews.  COVID-19 patients may be quite ill with severe respiratory symptoms, 
including coughing, trouble breathing, and shortness of breath.  They are probably wearing a mask and 
will likely encounter health care professionals who are themselves masked, gloved, and wearing face 
protection, impeding both verbal and visual doctor-patient communication.  Patients may find it difficult 
to answer questions, wish to hurry through the interview process, and downplay potentially risky 
behaviors such as smoking.  Even well-intentioned health care professionals may not conduct thorough 
interviews because of stress and overwork.  For example, in a large Chinese study (Table 3 of 18), patients 
with unknown smoking status were lumped together with non-smokers in a single non-smoking category 
(Never/unknown).  Thus, failure to correctly identify active and previous smokers at the time of hospital 
admission could reduce estimates of smoking prevalence among COVID-19 patients, relative to the 
general population.   
A second alternative explanation is “reverse causation”.  Patients hospitalized with COVID-19 may 
be simply less prone to use tobacco.  A potentially robust “reverse causation” hypothesis for reduced 
prevalence of smokers in the COVID-19 population is the enrichment of patients in that population with 
serious comorbidities that motivates them to quit, or avoid, smoking.  That is, COVID-19 patients with 
comorbidities could be less prone to smoke.  We call this explanation the “smoking cessation” hypothesis.  
Antismoking campaigns have effectively reduced smoking in recent decades. The smoking rate among 
American adults was 42-45% in the mid-20th Century.  It is now ~ 14% 19.  Antismoking campaigns 
emphasize that individuals with underlying medical conditions exacerbated by smoking—diabetes, 
cardiovascular disease, obesity, cancer--should quit.  Consequently, individuals with these conditions may 
smoke less (perhaps by several fold) or cease smoking all together.  Several important risk factors for 
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tobacco-related disease—hypertension, obesity, and diabetes--overlap substantially with COVID-19 risk 
factors.  It seems likely that such high-risk individuals have altered their behavior to smoke less or quit 
altogether.  If so, this population presents a lower smoking prevalence than the general population.  If 
individuals who quit smoking because of tobacco-related disease contract COVID-19 and become 
hospitalized, their low smoking prevalence is expected to reduce that of COVID-19 patients in general 
because patients with such comorbidities comprise a major fraction of the COVID-19 population 20.  In 
other words, we suggest that successful intervention in the high-risk groups during the pre-COVID-19 
years, by antismoking campaigns, medical providers, and family members, has reduced smoking 
prevalence in the COVID-19 population.  Also, many nursing homes prohibit smoking.  Nursing facilities 
contribute large numbers of patients to the COVID-19 population.  We judge that the “smoking cessation” 
mechanism may account for a significant fraction of the reduced prevalence of smokers in the COVID-19 
population.  Testing this hypothesis will require a focused research program.   Our judgement that 
“protection” is unlikely derives, in part, from considering the history of research on the negative 
correlation between smoking history and the lifetime risk of Parkinson’s disease (PD, see Note 1).  Despite 
repeated attempts, there are no reports of successful efforts to ameliorate Parkinson’s disease with 
nicotine patches or other nicotine replacement therapy.  
 
Testing the “Smoking Cessation” vs “Protection” Hypotheses 
Medical histories and records taken during hospital admission provide the currently available 
epidemiological data.  Oral histories of patient lifestyle are likely to be rushed or incomplete during a 
pandemic.  In contrast, smoking data from smoking prevention and cessation programs collected by 
health maintenance organizations (HMOs) are reliable 21.  Subjects typically enter these programs because 
they have a high risk of tobacco-related disease and wish to reduce their risk by smoking cessation 22-24.  
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In many cases, the programs follow patients for twelve months or more and classify them as “successful” 
and “unsuccessful” quitters.  Smoking status and participation in smoking cessation programs are now 
part of electronic medical records, which allow HMOs to routinely determine whether subjects have 
become COVID-19 patients.  
Smoking could both increase the probability of COVID-19 hospitalization by exacerbating 
smoking-related diseases and exert a protective effect by a still unidentified mechanism.  Mindful of this 
complication, preliminary studies could test the contrasting predictions made by the “smoking cessation” 
and “protection” hypotheses.   For individuals without pre-existing medical conditions (such as 
hypertension, chronic obstructive pulmonary disease (COPD), or diabetes) prior to hospitalization with 
COVID-19, the predictions are straightforward.  The “smoking cessation” hypothesis predicts that 
successful (ex-smokers) and unsuccessful quitters (active smokers) will present a similar incidence of 
COVID-19 hospitalizations during the pandemic.  In contrast, the “protection” hypothesis predicts that, in 
general, active smokers will present a lower incidence.  The predictions become more complicated for 
individuals with smoking-related diseases prior to COVID-19 hospitalization because continued smoking 
is expected to exacerbate these diseases.  For individuals with smoking-related diseases, the “smoking 
cessation” hypothesis predicts that successful quitters will present a similar, or lower, incidence of COVID-
19 hospitalization compared to unsuccessful ones because failure to quit could exacerbate COVID-19 
comorbidities.  Predictions for the “protection” hypothesis depend on whether the deleterious effects of 
continued smoking on COVID-19 comorbidities outweigh its protective effects.  Thus, predictions in this 
case are difficult to make a priori.  Such an analysis will make an important contribution to mechanistic 
discussions about the low smoking prevalence of COVID-19 patients.  
Predictions are also less clear for patients who have stopped smoking because they take 
varenicline—a nicotinic partial agonist—or because they use ENDSs.  Data on these subjects will increase 
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the interest of the studies. Confounding variables include the possibility that smokers put their hand near 
their mouths more often than non-smokers, increasing the likelihood of infection.  
Finally, it will also be important to know how many COVID-19 patients stopped smoking when 
they felt the irritation of initial COVID-19 symptoms. As HMOs treat more COVID-19 patients, and 
increasingly test members for SARS-CoV-2 infection and antibodies, their databases will become troves of 
information about the interactions between lifestyle choices, such as smoking, and COVID-19.  It will 
eventually be possible to query all tested members, including those who have not been hospitalized and 
those who stopped smoking voluntarily.  
This commentary emphasizes the knowledge to be gained by analyzing smoking behavior in depth 
before and during the COVID-19 pandemic.   If, over the upcoming years, the “smoking cessation” 
hypothesis increases support for health maintenance organizations, their antismoking campaigns deserve 
congratulations.  Their successful efforts at prevention and cessation will have mitigated harm among 
individuals at risk for tobacco-related disease and possibly COVID-19. 
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Note 1.  
More than 70 studies, beginning in 1959 25, report a negative correlation between smoking and PD.  These 
studies are both case-control and cohort. The overall average odds ratio for the PD effect is ~2; the odds 
of finding smokers in the PD patient population are half that of finding them in the PD-free controls. 
Data with animal models and cultured dopaminergic neurons further suggest that nicotine may underlie 
this negative correlation 26. A plausible biological mechanism proposes that the interaction between 
nicotine and nicotinic acetylcholine receptors in the endoplasmic reticulum (ER) reduces ER stress and the 
unfolded protein response 27 which, in turn, reduce the risk of PD.  
Alternatively, “reverse causality” could explain this negative correlation. Anecdotally, neurologists report 
that early-stage PD patients stop smoking, even though they display few or no minor motor symptoms. 
Mechanistically, this tendency could be explained by damage to dopaminergic neurons during the 
prodromal stage, so that the prodromal patient derives less reward from activation of the nicotinic 
receptors on those neurons 28,29. Regardless of the “reverse causality” mechanism, the result is that, 
several years later, when patients are diagnosed with PD, the PD population has a dearth of smokers and 
the non-PD population is comparatively enriched in smokers. This hypothesis postulates that the apparent 
neuroprotective effect of smoking occurs because PD patients are less likely to smoke—not because 
smokers are protected.  
A “reverse causality” mechanism for COVID-19 based on patient behavior (COVID-19 patients with severe 
co-morbidities smoke less, rather than that smokers are protected) is analogous to that for PD. 
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